Shulou(Shulou.com)11/24 Report--

CTOnews.com, December 26, according to the official Wechat account of "Optical Valley of China", a broad-spectrum HPV vaccine jointly developed by Wuhan Bowo Biology, an optical valley company, and a Shanghai related company, has received an ethical approval issued by the Australian Ethics Committee for Human Research and has completed the filing of the Australian Drug Administration (TGA) clinical trial, thus officially allowing it to enter the clinical trial. This is the first broad-spectrum HPV vaccine in the world to enter clinical trials.

CTOnews.com learned that persistent infection of human papillomavirus (HPV) is the primary cause of cervical cancer. In addition, it can also induce various types of cancers such as oropharyngeal and laryngeal cancer, sexually transmitted diseases such as condyloma acuminatum, and skin diseases such as verruca vulgaris and verruca plana.

At present, more than 200 types of HPV have been identified, and the highest price of HPV vaccine on the market is 9-valent vaccine, but it only has protective effect on the covered type, but has no protective effect on other types other than 9-valent vaccine. Increasing the price of HPV vaccine alone will not only increase the cost of vaccine, but also reduce the accessibility of vaccine, which is very disadvantageous to the prevention and control of related diseases.

Bovo Biological CEO Wu Ke said that the broad-spectrum HPV vaccine developed by the company is the first broad-spectrum HPV vaccine in the world to enter the clinical stage, which in theory can prevent all more than 200 types of HPV infection and cervical cancer and other malignant tumors, with a wider scope of protection and lower production costs. It is hoped that after listing, it can become the "Terminator" of HPV virus infection and the resulting malignant tumors. It is expected that the HPV vaccine will be applied for clinical trial in China in 2023.

In addition, the inhaled novel coronavirus vaccine, independently developed and produced by the company, has also obtained approval for clinical trials in Brazil and Singapore, and the next step will be to promote clinical progress as soon as possible.

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.